文献速递消化内镜消化道肿瘤与早癌

结肠胶囊内镜筛查结直肠癌家族史人群的结直肠肿瘤

Colon capsule endoscopy to screen for colorectal neoplasia in those with family histories of colorectal cancer.
PubMed 文献 · Gastrointest Endosc · 2017-05-26

本研究前瞻性评估结肠胶囊内镜(CCE)在结直肠癌(CRC)患者一级亲属(FDRs)中的筛查准确性,以光学结肠镜(OC)分段揭盲为参考标准。共纳入177名FDRs,CCE对≥6 mm息肉的灵敏度为91%、特异度为88%,对≥10 mm息肉灵敏度为89%、特异度95%。结论认为CCE是筛查CRC患者FDRs的准确方法,可作为拒绝或不适合结肠镜筛查者的替代选择。

要点

  • CCE对≥6 mm息肉灵敏度91%(95% CI 81-96),特异度88%(95% CI 81-93)。
  • CCE对≥10 mm息肉灵敏度89%,特异度95%。
  • CCE后转诊结肠镜率分别为37%和18%。

核心结论

  • CCE是筛查CRC患者FDRs的准确方法,可作为拒绝或不适合结肠镜筛查者的替代选择。

研究设计与样本

  • 前瞻性研究,连续纳入211例索引病例的177名FDRs(中位年龄57.0岁,54.8%女性),均完成CCE和次日OC,以OC分段揭盲为参考标准。

主要发现

  • CCE检出56名≥6 mm息肉FDRs中的51名(灵敏度91%;95% CI,81-96),将121名无≥6 mm病变者中的107名正确分类为阴性(特异度88%;95% CI,81-93)。
  • ≥6 mm病变的 per-patient 阳性预测值为78%(95% CI,67-87),阴性预测值为95%(95% CI,90-98)。
  • CCE检出27名≥10 mm息肉患者中的24名,将150名中的142名正确分类为阴性,对应灵敏度89%和特异度95%。
  • CCE后转诊结肠镜率分别为37%和18%。

临床怎么用

  • 作者认为CCE是筛查CRC患者FDRs的准确方法,可作为拒绝或不适合结肠镜筛查者的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Colon capsule endoscopy (CCE) has been recognized as an alternative for colorectal cancer (CRC) screening in average-risk people. Our aim was to prospectively assess the accuracy of CCE as a screening tool in first-degree relatives (FDRs) of people with CRC by using optical colonoscopy (OC) with segmental unblinding as the reference standard. METHODS: Consecutive patients admitted with a CRC diagnosis (index cases) were prospectively evaluated and invited to contact their FDRs. Available FDRs were invited to undergo CCE and OC on the following day, with segmental unblinding of CCE results. Sensitivity, specificity, and predictive values/negative predictive values (PPV/NPV) of CCE were assessed for detecting patients with any polyp ≥6 mm and ≥10 mm. RESULTS: A total of 177 FDRs (median age 57.0 years, 54.8% female) identified from 211 index cases were included. Both CCE and OC were completed in all the included FDRs. Overall, CCE identified 51 of 56 FDRs with polyps ≥6 mm (sensitivity 91%; 95% CI, 81-96) and correctly classified as negative 107 of 121 participants without lesions ≥6 mm (specificity 88%; 95% CI, 81-93). Per-patient positive and negative predictive values for ≥6 mm lesions were 78% (95% CI, 67-87) and 95% (95% CI, 90-98), respectively. CCE detected 24 of 27 patients with polyps ≥10 mm and correctly classified as negative 142 of 150 patients, corresponding to 89% sensitivity and 95% specificity. Post-CCE referral rates to colonoscopy were 37% and 18%, respectively. CONCLUSIONS: CCE is an accurate method to screen FDRs of patients with CRC and could be offered as an alternative to those who decline or are unfit for colonoscopy screening. (Clinical trial registration number: NCT01184781.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Parodi A, Vanbiervliet G, Hassan C, et al. Colon capsule endoscopy to screen for colorectal neoplasia in those with family histories of colorectal cancer. Gastrointest Endosc. 2017. PMID: 28554656. doi:10.1016/j.gie.2017.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。